Year in Review

Nivolumab plus ipilimumab combined with 2 cycles of chemotherapy for the treatment of advanced NSCLC demonstrates durable efficacy compared with 4 cycles of chemotherapy alone in a 2-year follow-up study. Read More ›

After more than 4 years of follow-up, patients with advanced NSCLC treated with nivolumab plus ipilimumab maintained overall survival rates. Read More ›

Durvalumab plus standard-of-care chemotherapy and durvalumab with tremelimumab plus standard-of-care chemotherapy were both associated with better progression-free survival compared with standard-of-care chemotherapy alone in the treatment of metastatic NSCLC. Read More ›

Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
Dual immune checkpoint inhibitor therapy provides significant and durable survival benefits over chemotherapy as first-line treatment in metastatic NSCLC. Read More ›

Key Abstracts from ASCO 2021 in NSCLC
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Read More ›

Adjuvant atezolizumab extends disease-free survival after adjuvant chemotherapy compared with best supportive care after adjuvant chemotherapy in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC). Read More ›

Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing. Read More ›

Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone. Read More ›

Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel. Read More ›

Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either MET, EGFR, or KRAS in patients with EGFR-mutated metastatic non–small-cell lung cancer (NSCLC). Read More ›

Page 7 of 9